Seelos Therapeutics Inc - ESG Rating & Company Profile powered by AI
The ESG rating covers 17 United Nations SDGs including: 'Quality Education', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'. The webpage of Seelos Therapeutics Inc is assembled by All Street Sevva using advanced Cognitive Robots. Other companies in the rating peer group for Seelos Therapeutics Inc are displayed below.
Seelos Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 4.0, social score of 1.3 and governance score of 3.4.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1800 | Wuhan Hiteck Biological Pharma Co Ltd | 3.0 | Medium |
| 1800 | Zhejiang Jingxin Pharmaceutical Co Ltd | 3.0 | Medium |
| 1836 | Seelos Therapeutics Inc | 2.9 | Medium |
| 1836 | Aarey Drugs and Pharmaceuticals Ltd | 2.9 | Medium |
| 1836 | Alpha Teknova Inc | 2.9 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Seelos Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Seelos Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Seelos Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Seelos Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Seelos Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Seelos Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Seelos Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Seelos Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Seelos Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Seelos Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Seelos Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Seelos Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Seelos Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Seelos Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Seelos Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Seelos Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Seelos Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Seelos Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.